Karyopharm Therapeutics (NASDAQ:KPTI) Lowered to Hold Rating by StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other brokerages have also recently issued reports on KPTI. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Piper Sandler upped their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $0.77 on Friday. The company’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $0.89. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The stock has a market capitalization of $96.37 million, a PE ratio of -0.67 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same period last year, the firm earned ($0.30) earnings per share. On average, analysts anticipate that Karyopharm Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. Ikarian Capital LLC grew its position in shares of Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $167,000. Point72 DIFC Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $494,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $143,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).